HilliardFSeiglerMD
General Surgery • Durham, NCSurgical Oncology (Other than Breast)
Professor, Surgery, Duke University School of Medicine
Are you Dr. Seigler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
508 Fulton St
Durham, NC 27705Phone+1 919-286-6939
Summary
- Dr. Hilliard Seigler, MD is a general surgeon in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina. He is affiliated with Durham Veterans Affairs Medical Center and is a Professor at Duke University School of Medicine.
Education & Training
University of North Carolina HospitalsResidency, Plastic Surgery - Integrated, 1963 - 1965- University of North Carolina HospitalsResidency, Surgery, 1960 - 1963
University of North Carolina at Chapel Hill School of MedicineClass of 1960
Certifications & Licensure
NC State Medical License 1960 - 2023- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal Start of enrollment: 1997 Jul 01
Publications & Presentations
PubMed
- 101 citationsMalignant melanoma and pregnancy.Douglas S. Reintgen, Kenneth S. McCarty, Robin T. Vollmer, Edwin B. Cox, Hillard F. Seigler
Cancer. 1985-03-15 - 7852 citationsMutations of the BRAF gene in human cancerHelen Davies, Graham R. Bignell, Charles Cox, Philip J. Stephens, Sarah Edkins
Nature. 2002-06-27 - 58 citationsEvaluation of recurrent glomerulonephritis in kidney allograftsMaria Morzycka, Byron P. Croker, Hilliard F. Seigler, C. Craig Tisher
The American Journal of Medicine. 1982-04-01
Press Mentions
- Preclinical Evaluation of Cancer Immune Therapy Using Patient‐Derived Tumor Antigen‐Specific T Cells in a Novel Xenograft PlatformFebruary 2nd, 2021
Professional Memberships
- Member
